Outsourcing is driving biopharma efficiency and scale, including in the drug discovery area and early phase development.
In this PharmTech video feature, I highlight the week’s industry news in an easy-to-consume format. New roundups drop every ...
Marcio Temtem, vice president, Strategic Business Management, Hovione, addresses molecule complexity, speed, and ...
ACG’s Shirwal site is the first pharmaceutical packaging site in the WEF Lighthouse Network, using digital tools to cut ...
Dr. Stacy Lindborg is president and CEO of IMUNON, a clinical-stage company in phase 3 development with a lead DNA-mediated ...
In this forward-looking whitepaper, Blue Mountain explores how agentic AI —autonomous, context-aware AI agents—could ...
FDA Commissioner Marty Makary, M.D., M.P.H., characterized the program as a “bold step” to bring manufacturing back to the US and make the domestic sector more resilient and competitive. This program ...
The companies’ “Change the Target. Change What’s Possible” targets the potential of Factor XIa inhibition in the development ...
FDA priority review seeks marstacimab label expansion to ≥6 years with inhibitors and ages 6–11 without inhibitors, addressing populations with limited efficacy from factor replacement and high unmet ...
Priority Review was granted by FDA for the first line metastatic TNBC treatment. Datroway significantly improved survival ...
Nine recommendations for extending therapeutic indications reflect ongoing lifecycle management and utility expansion of ...
Cellares. Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results